Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03499353
Title Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer

Her2-receptor negative breast cancer



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.